v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net income $ 215,817 $ 179,471
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation, amortization and accretion 68,163 47,265
Adjustment to the fair value of asset retirement obligation 0 (4,727)
Amortization of debt-related costs 3,343 3,343
Impairment of intangible assets 31,000 0
Change in fair value of contingent liabilities (28,586) 982
Inventory adjustments 3,569 2,869
Stock-based compensation 57,923 68,020
Net loss (gain) on investment in equity securities 6,795 (871)
Charges incurred pursuant to acquired in-process research and development 24,252 5,413
Deferred taxes (24,620) 23,379
Long-term income tax payable and other long-term liabilities (11,168) (2,754)
Gain on sale of business, net of transaction costs (59,444) 0
Gain on conversion of Installment Note (2,525) 0
Other 9,832 5,522
Changes in operating assets and liabilities, excluding impact of acquisitions:    
Accounts receivable 7,953 (15,821)
Inventory (2,826) (6,325)
Other current and long-term assets (4,643) (6,344)
Accounts payable 6,110 29,473
Accrued expenses and other current and long-term liabilities 18,359 (28,932)
Net cash provided by operating activities 319,304 299,963
Cash flows from investing activities:    
Capital expenditures (7,607) (27,301)
Acquisition of in-process research and development (5,646) (5,413)
Milestone payments related to prior acquisition (13,002) 0
Proceeds from sale of business, net of transaction costs 24,212 0
Proceeds from sale of assets 5,000 0
Principal payments from notes receivable 1,000 0
Proceeds from sale of equity securities 8,559 0
Purchases of investment in equity securities 0 (5,000)
Net cash provided by (used in) investing activities 12,828 (615,658)
Cash flows from financing activities:    
Payments of long-term debt and other borrowings (664) (757)
Proceeds from stock option exercises 9,581 6,473
Proceeds from employee stock purchase plan 4,722 3,726
Payments for minimum statutory tax withholding related to net share settlement of equity awards (21,217) (25,240)
Repurchase of common stock 0 (200,000)
Net cash used in financing activities (7,578) (215,798)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (47) 711
Net increase (decrease) in cash, cash equivalents and restricted cash 324,507 (530,782)
Cash, cash equivalents and restricted cash, beginning of period 360,826 914,486
Cash, cash equivalents and restricted cash, end of period 685,333 383,704
Reconciliation to amounts within the condensed consolidated balance sheets    
Cash and cash equivalents 683,610 382,006
Restricted cash included in other long-term assets 1,723 1,698
Cash, cash equivalents and restricted cash at end of period 685,333 383,704
Schedule of non-cash investing and financing activities    
Additions of property, plant and equipment included in liabilities 1,562 5,317
Modification of lease agreement 1,939 5,789
Receipt of notes related to sale of business 94,000 0
Conversion of notes receivable into preferred stock 70,000 0
Contingent consideration assets related to sale of business 6,500 0
Contingent consideration liabilities related to the acquisitions 0 96,842
Excise tax payable on net common stock repurchases 0 1,205
Right-of-use asset obtained in exchange for operating lease obligation 4,822 0
Right-of-use asset obtained in exchange for finance lease obligation 316 150
Lantheus Biosciences Ltd    
Cash flows from investing activities:    
Acquisition of net of cash acquired 312 (309,011)
Evergreen Theragnostics    
Cash flows from investing activities:    
Acquisition of net of cash acquired $ 0 $ (268,933)